查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1751269

美国吸入麻醉市场规模、份额、趋势分析报告：按药物、应用、最终用途、细分市场预测，2025-2030 年

U.S. Inhalation Anesthesia Market Size, Share & Trends Analysis Report By Drug (Sevoflurane, Desflurane), By Application (Induction, Maintenance), By End Use (Hospitals, ASC), And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 80 Pages | 商品交期: 2-10个工作天内

价格

美国吸入麻醉市场的成长与趋势：

根据Grand View Research, Inc.的最新报告，美国吸入麻醉市场规模预计到2030年将达到10.6亿美元，预测期内的复合年增长率为6.1%。

市场成长归因于缩短住院时间和增加外科手术的需求不断增长。吸入麻醉透过呼吸道输送麻醉剂，提供更可控、更有效的镇静，且经济高效、安全可靠，与静脉麻醉相比，可带来更好的患者预后。

吸入麻醉可产生可逆性的无意识和麻木状态，是无痛手术的必要手段。它广泛应用于各种外科手术的全身麻醉，尤其门诊病人、儿童以及有针头恐惧症的患者。吸入麻醉剂也可用于诊断手术，并可用于手术室外的ICU镇静、气喘患者的镇静等。此外，氧化亚氮等麻醉剂可在牙科手术中提供适度的镇静。

根据美国国家医学图书馆的数据，美国每年约有4000万至5000万例大型手术。吸入麻醉对于癌症诊断和切片检查至关重要，美国在这些过程中提供舒适感。美国国家癌症研究所估计，2024年美国将新增约2,001,140例癌症病例，其中14,910例为儿童和青少年。癌症发生率的上升预计将推动吸入麻醉的需求，尤其是在儿童和成人癌症治疗中。

美国吸入麻醉市场报告重点

  • 根据药剂，SEVOFLURANE製剂将主导美国吸入麻醉产业，到 2024 年将占据 75.5% 的最大销售份额。由于其在日间手术中的普及，可以快速实现深度麻醉并缩短恢復时间，因此需求增加。
  • 预计Isoflurane製剂部分在预测期内将显着成长。
  • 根据应用，维护阶段在 2024 年占据市场主导地位，收入份额最大。然而，预计引入阶段在预测期内将以显着的复合年增长率成长。
  • 按最终用途划分，医院部门在 2024 年占据美国吸入麻醉行业的最大收益占有率。
  • 在预计预测期内，门诊手术中心 (ASC) 最终用途部分将以 7.0% 的最快复合年增长率增长。
  • 预计未来几年，ASC 中越来越多的外科手术（包括整形外科、眼科、胃肠病学、泌尿系统、整形外科、泌尿科、妇科和足病学）将推动吸入麻醉的需求。

目录

第一章调查方法与范围

第二章执行摘要

第三章美国吸入麻醉市场变数、趋势与范围

  • 市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 商业环境分析
    • 产业分析-波特五力分析
    • PESTLE分析

第四章美国吸入麻醉市场：药物业务分析

  • 2024 年及 2030 年各药物市场占有率
  • 药品细分细分仪表板
  • 市场规模、预测与趋势分析（按药物，2018-2030 年）
  • SEVOFLURANE
  • DESFLURANE
  • Isoflurane
  • 其他的

第五章美国吸入麻醉市场：应用商业分析

  • 2024 年及 2030 年各应用领域的市场占有率
  • 应用程式细分仪表板
  • 市场规模、预测与趋势分析（按应用，2018-2030 年）
  • 介绍
  • 维护

第六章美国吸入麻醉市场：依最终用途的业务分析

  • 2024 年和 2030 年按最终用途分類的市场占有率
  • 最终用途细分仪表板
  • 按最终用途分類的市场规模、预测和趋势分析（2018-2030 年）
  • 医院
  • 门诊手术中心（ASC）
  • 其他的

第七章 竞争态势

  • 参与者概览
  • 企业市场分析
  • 公司分类
  • 战略地图
  • 公司简介/上市公司
    • Baxter
    • AbbVie Inc.
    • Piramal Enterprises Ltd.
    • Hikma Pharmaceuticals PLC
    • Halocarbon, LLC
    • Sandoz Group AG
    • Fresenius Kabi AG
Product Code: GVR-4-68040-570-5

U.S. Inhalation Anesthesia Market Growth & Trends:

The U.S. inhalation anesthesia market size is anticipated to reach USD 1.06 billion by 2030, growing at a CAGR of 6.1% during the forecast period, according to a new report by Grand View Research, Inc. The market's growth is attributed to the rising demand for shorter hospital stays and increasing surgical procedures. Inhalation anesthesia offers higher patient outcomes compared to intravenous anesthesia, as administering anesthetic agents through the respiratory tract allows for more controllable, effective sedation that is both cost-effective and safe.

Inhalation anesthesia creates a reversible state of unconsciousness and loss of sensation, making it essential for pain-free surgeries. It is widely used for general anesthesia in various surgical settings, especially in outpatient, pediatric, and needle-phobic patients. Inhalation anesthetics are also valuable in diagnostic procedures and can be utilized outside the operating room for ICU sedation or conditions such as status asthmaticus. In addition, agents such as nitrous oxide provide moderate sedation in dental settings.

According to the National Library of Medicine, around 40 to 50 million major surgeries are conducted annually in the U.S. Inhalation anesthesia is critical for cancer diagnoses and biopsies, offering comfort during these procedures. The National Cancer Institute estimates that in 2024, about 2,001,140 new cancer cases will be diagnosed in the U.S., including 14,910 cases in children and adolescents. This rising cancer incidence is expected to boost the demand for inhalation anesthesia, particularly in pediatric and adult oncology care.

U.S. Inhalation Anesthesia Market Report Highlights:

  • Based on drug, the sevoflurane drug dominated the U.S. inhalation anesthesia industry, accounting for the largest revenue share of 75.5% in 2024. The demand is driven by its popularity in day surgery due to the quick attainment of deep anesthesia and faster recovery times.
  • The isoflurane drug segment is expected to grow significantly over the forecast period.
  • Based on application, the maintenance phase dominated the market with the largest revenue share in 2024. However, the induction phase is expected to grow at a significant CAGR over the forecast period.
  • Based on end use, the hospitals segment led the U.S. inhalation anesthesia industry with the largest revenue share in 2024.
  • The Ambulatory Surgical Centers (ASC) end use segment is expected to grow at the fastest CAGR of 7.0% over the forecast period.
  • The growing number of surgical procedures, including orthopedics, ophthalmology, gastroenterology, ENT, cosmetic surgeries, urology, gynecology, and podiatry, in ASCs is expected to drive the demand for inhalation anesthesia in the coming years.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug
    • 1.2.2. Application
    • 1.2.3. End Use
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Inhalation Anesthesia Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. U.S. Inhalation Anesthesia Market: Service Business Analysis

  • 4.1. Drug Market Share, 2024 & 2030
  • 4.2. Drug Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Drug, 2018 to 2030 (USD Million)
  • 4.4. Sevoflurane
    • 4.4.1. Sevoflurane Market, 2018 - 2030 (USD Million)
  • 4.5. Desflurane
    • 4.5.1. Desflurane Market, 2018 - 2030 (USD Million)
  • 4.6. Isoflurane
    • 4.6.1. Isoflurane Market, 2018 - 2030 (USD Million)
  • 4.7. Others
    • 4.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. U.S. Inhalation Anesthesia Market: Formulation Business Analysis

  • 5.1. Application Market Share, 2024 & 2030
  • 5.2. Application Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 5.4. Induction
    • 5.4.1. Inhalation Anesthesia Market, for Induction, 2018 - 2030 (USD Million)
  • 5.5. Maintenance
    • 5.5.1. Inhalation Anesthesia Market, for Maintenance, 2018 - 2030 (USD Million)

Chapter 6. U.S. Inhalation Anesthesia Market: End Use Business Analysis

  • 6.1. End Use Market Share, 2024 & 2030
  • 6.2. End Use Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 6.4. Hospitals
    • 6.4.1. Inhalation Anesthesia Market, in Hospitals, 2018 - 2030 (USD Million)
  • 6.5. Ambulatory Surgical Centers (ASC)
    • 6.5.1. Inhalation Anesthesia Market, in Ambulatory Surgical Centers, 2018 - 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Inhalation Anesthesia Market, in Others, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Baxter
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. AbbVie Inc.
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Piramal Enterprises Ltd.
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Hikma Pharmaceuticals PLC
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Halocarbon, LLC
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Sandoz Group AG
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Fresenius Kabi AG
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 U.S. inhalation anesthesia market, by drug, 2018 - 2030 (USD Million)
  • Table 4 U.S. inhalation anesthesia market, by application, 2018 - 2030 (USD Million)
  • Table 5 U.S. inhalation anesthesia market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 U.S. inhalation anesthesia market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Drug outlook (USD Million)
  • Fig. 9 Application outlook (USD Million)
  • Fig. 10 End use outlook (USD Million)
  • Fig. 11 Competitive landscape
  • Fig. 12 U.S. inhalation anesthesia market dynamics
  • Fig. 13 U.S. inhalation anesthesia market: Porter's five forces analysis
  • Fig. 14 U.S. inhalation anesthesia market: Pestle analysis
  • Fig. 15 U.S. inhalation anesthesia market: Drug segment dashboard
  • Fig. 16 U.S. inhalation anesthesia market: Drug market share analysis, 2024 & 2030
  • Fig. 17 Sevoflurane market, 2018 - 2030 (USD Million)
  • Fig. 18 Desflurane market, 2018 - 2030 (USD Million)
  • Fig. 19 Isoflurane market, 2018 - 2030 (USD Million)
  • Fig. 20 Other drug market, 2018 - 2030 (USD Million)
  • Fig. 21 U.S. inhalation anesthesia market: Application segment dashboard
  • Fig. 22 U.S. inhalation anesthesia market: Application market share analysis, 2024 & 2030
  • Fig. 23 Induction U.S. inhalation anesthesia market, for induction, 2018 - 2030 (USD Million)
  • Fig. 24 Induction U.S. inhalation anesthesia market, for maintenance, 2018 - 2030 (USD Million)
  • Fig. 25 U.S. inhalation anesthesia market: End use segment dashboard
  • Fig. 26 U.S. inhalation anesthesia market: End use market share analysis, 2024 & 2030
  • Fig. 27 Induction U.S. inhalation anesthesia market, in Hospitals, 2018 - 2030 (USD Million)
  • Fig. 28 Induction U.S. inhalation anesthesia market, in Ambulatory Surgical Centers, 2018 - 2030 (USD Million)
  • Fig. 29 Induction U.S. inhalation anesthesia market, in Others, 2018 - 2030 (USD Million)
  • Fig. 30 Company categorization
  • Fig. 31 Company market position analysis
  • Fig. 32 Strategic framework